{"id":"acitretin-also-called-u0279","safety":{"commonSideEffects":[{"rate":"75-90","effect":"Mucocutaneous dryness (lips, mouth, skin)"},{"rate":"50-75","effect":"Cheilitis"},{"rate":"30-50","effect":"Pruritus"},{"rate":"40-60","effect":"Peeling and erythema"},{"rate":"10-25","effect":"Alopecia"},{"rate":"25-40","effect":"Elevated triglycerides"},{"rate":"10-20","effect":"Elevated liver enzymes"},{"rate":"10-15","effect":"Headache"},{"rate":"10-20","effect":"Photosensitivity"}]},"_chembl":{"chemblId":"CHEMBL1131","moleculeType":"Small molecule","molecularWeight":"326.44"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Acitretin is a second-generation retinoid that activates retinoid X receptors (RXR) and retinoid acid receptors (RAR), leading to altered transcription of genes involved in cell proliferation and differentiation. This mechanism reduces the excessive skin cell turnover characteristic of psoriasis and other keratinization disorders, promoting normalization of the epidermis.","oneSentence":"Acitretin is a retinoid that binds to retinoid receptors in the nucleus, modulating gene expression to reduce keratinocyte proliferation and promote differentiation.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:28:01.856Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Severe psoriasis, including erythrodermic and pustular forms"},{"name":"Lichen planus"},{"name":"Pityriasis rubra pilaris"},{"name":"Ichthyosis and keratinization disorders"}]},"trialDetails":[{"nctId":"NCT00832364","phase":"PHASE4","title":"Trial of an Injectable Biologic and U0279 as Combination Therapy for Severe Plaque-Type Psoriasis","status":"WITHDRAWN","sponsor":"Stiefel, a GSK Company","startDate":"2009-10","conditions":"Plaque Psoriasis","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Acitretin (also called U0279)","genericName":"Acitretin (also called U0279)","companyName":"Stiefel, a GSK Company","companyId":"stiefel-a-gsk-company","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Acitretin is a small molecule that acts as a retinoid receptor agonist. It is used to treat severe plaque-type psoriasis, as indicated by clinical trials such as NCT00832364.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}